Aldeyra Therapeutics Inc. [NASDAQ: ALDX] slipped around -0.15 points on Monday, while shares priced at $6.53 at the close of the session, down -2.25%. About a week ago, the company came up with the announcement of the block sales of a total of 4,580,361 common stock shares to Avidity Partners Management LP and Perceptive Advisors, LLC as per the company’s earlier announced at-the-market offering program.
The two leading healthcare-focused investment funds bought the offerings from Aldeyra at each share sold at a per-share price of $4.25. The company received total gross proceeds of almost $4.25, excluding commission deductions. The sales have been completed under the previous offering program and Aldeyra will make no further sales under the following program. The sales agent of the offering was Jefferies, LLC which operated under the at-the-market offering program.
Aldeyra Therapeutics Inc. stock is now 12.39% up from its year-to-date (YTD) trading value. ALDX Stock saw the intraday high of $6.85 and lowest of $6.15 per share. The company’s 52-week high price is 8.05, which means current price is +341.22% above from all time high which was touched on 07/17/20.
Compared to the average trading volume of 1.27M shares, ALDX reached a trading volume of 987658 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aldeyra Therapeutics Inc. [ALDX]?
Oppenheimer have made an estimate for Aldeyra Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 12, 2020. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on December 04, 2018, representing the official price target for Aldeyra Therapeutics Inc. stock. Previously, the target price had yet another raise from $23 to $30, while Cantor Fitzgerald kept a Overweight rating on ALDX stock.
The Average True Range (ATR) for Aldeyra Therapeutics Inc. is set at 0.54 The Price to Book ratio for the last quarter was 4.38, with the Price to Cash per share for the same quarter was set at 2.14.
How has ALDX stock performed recently?
Aldeyra Therapeutics Inc. [ALDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 38.94. With this latest performance, ALDX shares gained by 41.96% in over the last four-week period, additionally plugging by 4.31% over the last 6 months – not to mention a rise of 23.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALDX stock in for the last two-week period is set at 72.67, with the RSI for the last a single of trading hit 76.64, and the three-weeks RSI is set at 69.28 for Aldeyra Therapeutics Inc. [ALDX]. The present Moving Average for the last 50 days of trading for this stock 4.55, while it was recorded at 6.23 for the last single week of trading, and 4.68 for the last 200 days.
Aldeyra Therapeutics Inc. [ALDX]: Deeper insight into the fundamentals
Return on Total Capital for ALDX is now -75.62, given the latest momentum, and Return on Invested Capital for the company is -81.52. Return on Equity for this stock declined to -90.31, with Return on Assets sitting at -71.28. When it comes to the capital structure of this company, Aldeyra Therapeutics Inc. [ALDX] has a Total Debt to Total Equity ratio set at 30.69. Additionally, ALDX Total Debt to Total Capital is recorded at 23.48, with Total Debt to Total Assets ending up at 19.52. Long-Term Debt to Equity for the company is recorded at 30.22, with the Long-Term Debt to Total Capital now at 23.12.
Reflecting on the efficiency of the workforce at the company, Aldeyra Therapeutics Inc. [ALDX] managed to generate an average of -$3,041,342 per employee.Aldeyra Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.80 and a Current Ratio set at 12.80.
Earnings analysis for Aldeyra Therapeutics Inc. [ALDX]
With the latest financial reports released by the company, Aldeyra Therapeutics Inc. posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.49/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALDX.
Insider trade positions for Aldeyra Therapeutics Inc. [ALDX]
There are presently around $112 million, or 62.80% of ALDX stock, in the hands of institutional investors. The top three institutional holders of ALDX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 3,085,458, which is approximately 0% of the company’s market cap and around 4.90% of the total institutional ownership; PROSIGHT MANAGEMENT, LP, holding 2,035,340 shares of the stock with an approximate value of $13.6 million in ALDX stocks shares; and BLACKROCK INC., currently with $10.78 million in ALDX stock with ownership of nearly 1.866% of the company’s market capitalization.
Positions in Aldeyra Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 33 institutional holders increased their position in Aldeyra Therapeutics Inc. [NASDAQ:ALDX] by around 1,707,871 shares. Additionally, 40 investors decreased positions by around 2,601,315 shares, while 15 investors held positions by with 12,487,948 shares. The mentioned changes placed institutional holdings at 16,797,134 shares, according to the latest SEC report filing. ALDX stock had 10 new institutional investments in for a total of 222,450 shares, while 16 institutional investors sold positions of 1,241,128 shares during the same period.